Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TPMT | P51580 | 1/20 | 0.34 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065796 | 0.89 | PTGS2 (0.46) | PTGS2ALDH1A1TSHRTDP1CA2 | |
| Phosphine SCHEMBL28192251 | 0.87 | PTGS2 (0.44) | PTGS2ALDH1A1TSHRTDP1CA2 | |
| SCHEMBL1530477 | 0.82 | TTR (0.32) | TTRTPMTMCL1 | |
| SCHEMBL6838138 | 0.82 | RARG (0.39) | PTGS2ALDH1A1TSHRTDP1CA2 | |
| SCHEMBL694245 | 0.81 | CYP1A2 (0.36) | TTRTPMTCYP1A2 | |
| SCHEMBL12678876 | 0.80 | PTGS2 (0.40) | PTGS2ALDH1A1TSHRTDP1CA2 | |
| SCHEMBL482603 | 0.80 | DHFR (0.37) | PTGS2ALDH1A1TSHRTDP1CA2 | |
| SCHEMBL699612 | 0.80 | DHFR (0.37) | PTGS2ALDH1A1TSHRTDP1CA2 | |
| SCHEMBL482502 | 0.80 | CA2 (0.45) | PTGS2ALDH1A1TSHRTDP1CA2 | |
| SCHEMBL1530694 | 0.79 | TTR (0.48) | PTGS2ALDH1A1TDP1CA2TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111518036-A | Preparation method of Dasabovir key intermediate | 杭州勇诚睿生物科技有限公司 | 2020-08-11 | — | — | CN | claimed |
| CN-111518036-A | Preparation method of Dasabovir key intermediate | 杭州勇诚睿生物科技有限公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-111518036-A | Preparation method of Dasabovir key intermediate | 杭州勇诚睿生物科技有限公司 | 2020-08-11 | — | — | CN | disclosed |
| EP-3415504-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2018-12-19 | — | — | EP | disclosed |
| EP-2887941-B1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE IRELAND UNLIMITED CO (IE) | 2018-07-11 | — | — | EP | disclosed |
| EP-3056486-B1 | PROCESS FOR PREPARING INTERMEDIATES FOR ANTIVIRAL COMPOUNDS | ABBVIE IRELAND UNLIMITED CO (IE) | 2018-07-11 | — | — | EP | disclosed |
| US-9802903-B2 | Process for preparing antiviral compound | ABBVIE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9732045-B2 | Process for preparing antiviral compounds | ABBVIE INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9637478-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-2411352-B1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBVIE INC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090176784-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176784-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176784-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2009039135-A1 | N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039135-A1 | N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039134-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039134-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039127-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039127-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176784-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | PTGS2 1919/4885ALDH1A1 2117/4885TSHR 4588/4885 |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | PTGS2 1919/4885ALDH1A1 2117/4885TSHR 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.